A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast

Oukseub Lee, Katherine Page, David Ivancic, Irene Helenowski, Vamsi Parini, Megan E. Sullivan, Julie A. Margenthaler, Robert T. Chatterton, Borko Jovanovic, Barbara K. Dunn, Brandy M. Heckman-Stoddard, Kathleen Foster, Miguel Muzzio, Julia Shklovskaya, Silvia Skripkauskas, Piotr Kulesza, David Green, Nora M. Hansen, Kevin P. Bethke, Jacqueline S. Jeruss & 2 others Raymond Bergan, Seema A. Khan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel (4-OHT) to oral tamoxifen (oral-T) in women with ductal carcinoma in situ (DCIS). Methods: Twenty-seven pre- and postmenopausal women were randomized to 4-OHT (4 mg/day) or oral-T (20 mg/day) for 6 to 10 weeks before surgery. Plasma, nipple aspirate fluid, and breast adipose tissue concentrations of tamoxifen and its major metabolites were determined by liquid chromatography/tandem mass spectrometry. The primary endpoint was Ki67 labeling in DCIS lesions, measured by immunohistochemistry. In plasma, insulin-like growth factor-1 (IGFI), sex hormone-binding globulin (SHBG), and coagulation protein concentrations were determined. Results: Posttherapy Ki67 decreased by 3.4% in the 4-OHT and 5.1% in the oral-T group ( P ≤ 0.03 in both, between-group P = 0. 99). Mean plasma 4-OHT was 0.2 and 1.1 ng/mL in 4-OHT and oral groups, respectively (P = 0.0003), whereas mean breast adipose tissue concentrations of 4-OHT were 5.8 ng/g in the 4-OHT group and 5.4 ng/g in the oral group (P = 0.88). There were significant increases in plasma SHBG, factor VIII, and von Willebrand factor and a significant decrease in plasma IGFI with oral-T, but not with 4-OHT. The incidence of hot flashes was similar in both groups. Conclusions: The antiproliferative effect of 4-OHT gel applied to breast skin was similar to that of oral-T, but effects on endocrine and coagulation parameters were reduced. These findings support the further evaluation of local transdermal therapy for DCIS and breast cancer prevention.

Original languageEnglish (US)
Pages (from-to)3672-3682
Number of pages11
JournalClinical Cancer Research
Volume20
Issue number14
DOIs
StatePublished - Jul 15 2014
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Tamoxifen
Breast
Gels
Sex Hormone-Binding Globulin
Adipose Tissue
Nipple Aspirate Fluid
Hot Flashes
afimoxifene
4,17 beta-dihydroxy-4-androstene-3-one
Somatomedins
Tandem Mass Spectrometry
Liquid Chromatography
Immunohistochemistry
Placebos
Breast Neoplasms
Skin
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast. / Lee, Oukseub; Page, Katherine; Ivancic, David; Helenowski, Irene; Parini, Vamsi; Sullivan, Megan E.; Margenthaler, Julie A.; Chatterton, Robert T.; Jovanovic, Borko; Dunn, Barbara K.; Heckman-Stoddard, Brandy M.; Foster, Kathleen; Muzzio, Miguel; Shklovskaya, Julia; Skripkauskas, Silvia; Kulesza, Piotr; Green, David; Hansen, Nora M.; Bethke, Kevin P.; Jeruss, Jacqueline S.; Bergan, Raymond; Khan, Seema A.

In: Clinical Cancer Research, Vol. 20, No. 14, 15.07.2014, p. 3672-3682.

Research output: Contribution to journalArticle

Lee, O, Page, K, Ivancic, D, Helenowski, I, Parini, V, Sullivan, ME, Margenthaler, JA, Chatterton, RT, Jovanovic, B, Dunn, BK, Heckman-Stoddard, BM, Foster, K, Muzzio, M, Shklovskaya, J, Skripkauskas, S, Kulesza, P, Green, D, Hansen, NM, Bethke, KP, Jeruss, JS, Bergan, R & Khan, SA 2014, 'A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast', Clinical Cancer Research, vol. 20, no. 14, pp. 3672-3682. https://doi.org/10.1158/1078-0432.CCR-13-3045
Lee, Oukseub ; Page, Katherine ; Ivancic, David ; Helenowski, Irene ; Parini, Vamsi ; Sullivan, Megan E. ; Margenthaler, Julie A. ; Chatterton, Robert T. ; Jovanovic, Borko ; Dunn, Barbara K. ; Heckman-Stoddard, Brandy M. ; Foster, Kathleen ; Muzzio, Miguel ; Shklovskaya, Julia ; Skripkauskas, Silvia ; Kulesza, Piotr ; Green, David ; Hansen, Nora M. ; Bethke, Kevin P. ; Jeruss, Jacqueline S. ; Bergan, Raymond ; Khan, Seema A. / A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 14. pp. 3672-3682.
@article{788f111cee104576b888c60c2d572473,
title = "A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast",
abstract = "Purpose: Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel (4-OHT) to oral tamoxifen (oral-T) in women with ductal carcinoma in situ (DCIS). Methods: Twenty-seven pre- and postmenopausal women were randomized to 4-OHT (4 mg/day) or oral-T (20 mg/day) for 6 to 10 weeks before surgery. Plasma, nipple aspirate fluid, and breast adipose tissue concentrations of tamoxifen and its major metabolites were determined by liquid chromatography/tandem mass spectrometry. The primary endpoint was Ki67 labeling in DCIS lesions, measured by immunohistochemistry. In plasma, insulin-like growth factor-1 (IGFI), sex hormone-binding globulin (SHBG), and coagulation protein concentrations were determined. Results: Posttherapy Ki67 decreased by 3.4{\%} in the 4-OHT and 5.1{\%} in the oral-T group ( P ≤ 0.03 in both, between-group P = 0. 99). Mean plasma 4-OHT was 0.2 and 1.1 ng/mL in 4-OHT and oral groups, respectively (P = 0.0003), whereas mean breast adipose tissue concentrations of 4-OHT were 5.8 ng/g in the 4-OHT group and 5.4 ng/g in the oral group (P = 0.88). There were significant increases in plasma SHBG, factor VIII, and von Willebrand factor and a significant decrease in plasma IGFI with oral-T, but not with 4-OHT. The incidence of hot flashes was similar in both groups. Conclusions: The antiproliferative effect of 4-OHT gel applied to breast skin was similar to that of oral-T, but effects on endocrine and coagulation parameters were reduced. These findings support the further evaluation of local transdermal therapy for DCIS and breast cancer prevention.",
author = "Oukseub Lee and Katherine Page and David Ivancic and Irene Helenowski and Vamsi Parini and Sullivan, {Megan E.} and Margenthaler, {Julie A.} and Chatterton, {Robert T.} and Borko Jovanovic and Dunn, {Barbara K.} and Heckman-Stoddard, {Brandy M.} and Kathleen Foster and Miguel Muzzio and Julia Shklovskaya and Silvia Skripkauskas and Piotr Kulesza and David Green and Hansen, {Nora M.} and Bethke, {Kevin P.} and Jeruss, {Jacqueline S.} and Raymond Bergan and Khan, {Seema A.}",
year = "2014",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-13-3045",
language = "English (US)",
volume = "20",
pages = "3672--3682",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast

AU - Lee, Oukseub

AU - Page, Katherine

AU - Ivancic, David

AU - Helenowski, Irene

AU - Parini, Vamsi

AU - Sullivan, Megan E.

AU - Margenthaler, Julie A.

AU - Chatterton, Robert T.

AU - Jovanovic, Borko

AU - Dunn, Barbara K.

AU - Heckman-Stoddard, Brandy M.

AU - Foster, Kathleen

AU - Muzzio, Miguel

AU - Shklovskaya, Julia

AU - Skripkauskas, Silvia

AU - Kulesza, Piotr

AU - Green, David

AU - Hansen, Nora M.

AU - Bethke, Kevin P.

AU - Jeruss, Jacqueline S.

AU - Bergan, Raymond

AU - Khan, Seema A.

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Purpose: Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel (4-OHT) to oral tamoxifen (oral-T) in women with ductal carcinoma in situ (DCIS). Methods: Twenty-seven pre- and postmenopausal women were randomized to 4-OHT (4 mg/day) or oral-T (20 mg/day) for 6 to 10 weeks before surgery. Plasma, nipple aspirate fluid, and breast adipose tissue concentrations of tamoxifen and its major metabolites were determined by liquid chromatography/tandem mass spectrometry. The primary endpoint was Ki67 labeling in DCIS lesions, measured by immunohistochemistry. In plasma, insulin-like growth factor-1 (IGFI), sex hormone-binding globulin (SHBG), and coagulation protein concentrations were determined. Results: Posttherapy Ki67 decreased by 3.4% in the 4-OHT and 5.1% in the oral-T group ( P ≤ 0.03 in both, between-group P = 0. 99). Mean plasma 4-OHT was 0.2 and 1.1 ng/mL in 4-OHT and oral groups, respectively (P = 0.0003), whereas mean breast adipose tissue concentrations of 4-OHT were 5.8 ng/g in the 4-OHT group and 5.4 ng/g in the oral group (P = 0.88). There were significant increases in plasma SHBG, factor VIII, and von Willebrand factor and a significant decrease in plasma IGFI with oral-T, but not with 4-OHT. The incidence of hot flashes was similar in both groups. Conclusions: The antiproliferative effect of 4-OHT gel applied to breast skin was similar to that of oral-T, but effects on endocrine and coagulation parameters were reduced. These findings support the further evaluation of local transdermal therapy for DCIS and breast cancer prevention.

AB - Purpose: Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. We conducted a randomized, double-blind, placebo-controlled phase II trial comparing transdermal 4-hydroxytamoxifen gel (4-OHT) to oral tamoxifen (oral-T) in women with ductal carcinoma in situ (DCIS). Methods: Twenty-seven pre- and postmenopausal women were randomized to 4-OHT (4 mg/day) or oral-T (20 mg/day) for 6 to 10 weeks before surgery. Plasma, nipple aspirate fluid, and breast adipose tissue concentrations of tamoxifen and its major metabolites were determined by liquid chromatography/tandem mass spectrometry. The primary endpoint was Ki67 labeling in DCIS lesions, measured by immunohistochemistry. In plasma, insulin-like growth factor-1 (IGFI), sex hormone-binding globulin (SHBG), and coagulation protein concentrations were determined. Results: Posttherapy Ki67 decreased by 3.4% in the 4-OHT and 5.1% in the oral-T group ( P ≤ 0.03 in both, between-group P = 0. 99). Mean plasma 4-OHT was 0.2 and 1.1 ng/mL in 4-OHT and oral groups, respectively (P = 0.0003), whereas mean breast adipose tissue concentrations of 4-OHT were 5.8 ng/g in the 4-OHT group and 5.4 ng/g in the oral group (P = 0.88). There were significant increases in plasma SHBG, factor VIII, and von Willebrand factor and a significant decrease in plasma IGFI with oral-T, but not with 4-OHT. The incidence of hot flashes was similar in both groups. Conclusions: The antiproliferative effect of 4-OHT gel applied to breast skin was similar to that of oral-T, but effects on endocrine and coagulation parameters were reduced. These findings support the further evaluation of local transdermal therapy for DCIS and breast cancer prevention.

UR - http://www.scopus.com/inward/record.url?scp=84904399469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904399469&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-3045

DO - 10.1158/1078-0432.CCR-13-3045

M3 - Article

VL - 20

SP - 3672

EP - 3682

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -